ATE552347T1 - Oligonukleotidverbindung und verfahren zur behandlung von nidovirusinfektionen - Google Patents
Oligonukleotidverbindung und verfahren zur behandlung von nidovirusinfektionenInfo
- Publication number
- ATE552347T1 ATE552347T1 AT04815419T AT04815419T ATE552347T1 AT E552347 T1 ATE552347 T1 AT E552347T1 AT 04815419 T AT04815419 T AT 04815419T AT 04815419 T AT04815419 T AT 04815419T AT E552347 T1 ATE552347 T1 AT E552347T1
- Authority
- AT
- Austria
- Prior art keywords
- nidovirus
- compound
- infections
- treating
- oligonucleotide compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 2
- 208000015181 infectious disease Diseases 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 2
- 101710163270 Nuclease Proteins 0.000 abstract 1
- 108091027544 Subgenomic mRNA Proteins 0.000 abstract 1
- 210000004102 animal cell Anatomy 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 230000002103 transcriptional effect Effects 0.000 abstract 1
- 230000029812 viral genome replication Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53270103P | 2003-12-24 | 2003-12-24 | |
| US11/022,358 US20050171044A1 (en) | 2003-12-24 | 2004-12-22 | Oligonucleotide compound and method for treating nidovirus infections |
| PCT/US2004/043341 WO2005065268A2 (en) | 2003-12-24 | 2004-12-23 | Oligonucleotide compound and method for treating nidovirus infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE552347T1 true ATE552347T1 (de) | 2012-04-15 |
Family
ID=34752430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04815419T ATE552347T1 (de) | 2003-12-24 | 2004-12-23 | Oligonukleotidverbindung und verfahren zur behandlung von nidovirusinfektionen |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US20050171044A1 (de) |
| EP (1) | EP1704243B1 (de) |
| AT (1) | ATE552347T1 (de) |
| AU (1) | AU2004311826B2 (de) |
| CA (1) | CA2550642C (de) |
| WO (1) | WO2005065268A2 (de) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2627917T3 (es) | 2004-06-28 | 2017-08-01 | The University Of Western Australia | Oligonucleótidos no codificantes para la inducción de la omisión exónica y métodos de uso de los mismos |
| US8129352B2 (en) | 2004-09-16 | 2012-03-06 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating ssRNA viral infection |
| US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| WO2007030691A2 (en) * | 2005-09-08 | 2007-03-15 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating picornavirus infection |
| LT2735568T (lt) * | 2006-05-10 | 2017-11-27 | Sarepta Therapeutics, Inc. | Oligonukleotido analogai, turintys katijonines jungtis tarp subvienetų |
| US8785407B2 (en) * | 2006-05-10 | 2014-07-22 | Sarepta Therapeutics, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
| EP3133160B1 (de) | 2008-10-24 | 2018-12-12 | Sarepta Therapeutics, Inc. | Exon-skipping-zusammensetzungen für dmd |
| HUE040445T2 (hu) | 2009-11-12 | 2019-03-28 | Univ Western Australia | Antiszensz molekulák és eljárások betegségek kezelésére |
| AU2010319314C1 (en) | 2009-11-13 | 2016-09-01 | Sarepta Therapeutics, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| KR101981705B1 (ko) | 2010-05-28 | 2019-05-24 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체 |
| US8198429B2 (en) | 2010-08-09 | 2012-06-12 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
| WO2012031243A2 (en) | 2010-09-03 | 2012-03-08 | Avi Biopharma, Inc. | dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS |
| AU2011367230B2 (en) | 2011-05-05 | 2017-08-10 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| KR20140097398A (ko) | 2011-11-18 | 2014-08-06 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 기능적으로-변형된 올리고뉴클레오티드 및 이의 서브유니트 |
| US9217148B2 (en) | 2013-03-14 | 2015-12-22 | Sarepta Therapeutics, Inc. | Exon skipping compositions for treating muscular dystrophy |
| HK1220154A1 (zh) | 2013-03-15 | 2017-04-28 | Sarepta Therapeutics, Inc. | 改进的用於治疗肌营养不良的组合物 |
| US11020417B2 (en) | 2015-06-04 | 2021-06-01 | Sarepta Therapeutics, Inc | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
| JP7250520B2 (ja) | 2016-04-13 | 2023-04-03 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | 組換えアルテリウイルスレプリコン系およびその使用 |
| JP7788787B2 (ja) * | 2016-12-05 | 2025-12-19 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | 遺伝子発現増強のための組成物および方法 |
| CA3046504A1 (en) | 2016-12-15 | 2018-06-21 | Meharry Medical College | Antiviral agents |
| CN118127019A (zh) | 2018-05-22 | 2024-06-04 | Ionis制药公司 | Apol1表达的调节剂 |
| BR112022021562A2 (pt) * | 2020-04-23 | 2023-02-07 | The J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Gladstone | Partículas interferentes terapêuticas para o coronavírus |
| WO2021226485A2 (en) * | 2020-05-08 | 2021-11-11 | Oregon State University | Antisense therapeutics for betacoronavirus treatment |
| WO2022056117A1 (en) * | 2020-09-10 | 2022-03-17 | Avidity Biosciences, Inc. | Nucleic acid-polypeptide compositions and uses thereof |
| EP4008785A1 (de) * | 2020-12-03 | 2022-06-08 | Justus-Liebig-Universität Gießen | Zirkuläre nukleinsäuren und verwendungen davon zur beeinflussung der genomexpression und zur proliferation von coronaviren |
| WO2022159448A1 (en) * | 2021-01-19 | 2022-07-28 | The Jackson Laboratory | Subgenomic rnas for evaluating viral infection |
| JPWO2022230974A1 (de) * | 2021-04-28 | 2022-11-03 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5185444A (en) * | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| GB9510718D0 (en) * | 1995-05-26 | 1995-07-19 | Sod Conseils Rech Applic | Antisense oligonucleotides |
| US7094765B1 (en) * | 1999-01-29 | 2006-08-22 | Avi Biopharma, Inc. | Antisense restenosis composition and method |
| KR20010102992A (ko) * | 1999-01-29 | 2001-11-17 | 추후보정 | 표적 ｒｎａ를 검출하는 비-침입적 방법 |
| EP1238071B1 (de) * | 1999-11-29 | 2008-04-23 | Avi Biopharma, Inc. | Gegen bakterielle 16s und 23s rrnas gerichtete ungeladene antisense oligonukleotide und deren verwendungen |
| WO2001049775A2 (en) * | 2000-01-04 | 2001-07-12 | Avi Biopharma, Inc. | Antisense antibacterial cell division composition and method |
| AU5752601A (en) * | 2000-05-04 | 2001-11-12 | Avi Biopharma Inc | Splice-region antisense composition and method |
| EP1301525B1 (de) * | 2000-07-06 | 2015-09-02 | Sarepta Therapeutics, Inc. | Transformation einer stammzellen enthaltenden, mit einem den wachstumsfaktor beta (tgf-beta) blockierenden mittel behandelten zusammensetzung und entsprechendes verfahren dazu |
| US6828105B2 (en) * | 2001-10-16 | 2004-12-07 | Avi Biopharma, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
| US20030224353A1 (en) * | 2001-10-16 | 2003-12-04 | Stein David A. | Antisense antiviral agent and method for treating ssRNA viral infection |
| EP1503762A2 (de) * | 2002-05-10 | 2005-02-09 | Teva Pharmaceutical Industries Ltd. | Neue kristalline formen von gatifloxacin |
| US20060257852A1 (en) * | 2003-04-10 | 2006-11-16 | Chiron Corporation | Severe acute respiratory syndrome coronavirus |
| US7339051B2 (en) * | 2003-04-28 | 2008-03-04 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (SARS) |
| AU2004235396B2 (en) * | 2003-04-29 | 2010-11-25 | Sarepta Therapeutics, Inc. | Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells |
| WO2005000234A2 (en) * | 2003-06-12 | 2005-01-06 | Sars Scientific Corp. | Novel coronavirus inhibitors |
| WO2005013905A2 (en) * | 2003-08-07 | 2005-02-17 | Avi Biopharma, Inc. | SENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING ssRNA VIRAL INFECTION |
| AU2005327188C9 (en) * | 2004-07-02 | 2011-09-22 | Avi Biopharma, Inc. | Antisense antibacterial method and compound |
| US8129352B2 (en) * | 2004-09-16 | 2012-03-06 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating ssRNA viral infection |
| LT2735568T (lt) * | 2006-05-10 | 2017-11-27 | Sarepta Therapeutics, Inc. | Oligonukleotido analogai, turintys katijonines jungtis tarp subvienetų |
| US8785407B2 (en) * | 2006-05-10 | 2014-07-22 | Sarepta Therapeutics, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
-
2004
- 2004-12-22 US US11/022,358 patent/US20050171044A1/en not_active Abandoned
- 2004-12-23 AU AU2004311826A patent/AU2004311826B2/en not_active Ceased
- 2004-12-23 CA CA 2550642 patent/CA2550642C/en not_active Expired - Fee Related
- 2004-12-23 AT AT04815419T patent/ATE552347T1/de active
- 2004-12-23 EP EP20040815419 patent/EP1704243B1/de not_active Expired - Lifetime
- 2004-12-23 WO PCT/US2004/043341 patent/WO2005065268A2/en not_active Ceased
-
2006
- 2006-05-10 US US11/432,155 patent/US20070037763A1/en not_active Abandoned
-
2008
- 2008-04-25 US US12/109,856 patent/US8759307B2/en active Active
-
2014
- 2014-06-04 US US14/295,665 patent/US20150126722A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004311826B2 (en) | 2011-04-28 |
| US20090012280A1 (en) | 2009-01-08 |
| EP1704243A2 (de) | 2006-09-27 |
| US20070037763A1 (en) | 2007-02-15 |
| AU2004311826A1 (en) | 2005-07-21 |
| CA2550642A1 (en) | 2005-07-21 |
| WO2005065268A2 (en) | 2005-07-21 |
| EP1704243B1 (de) | 2012-04-04 |
| EP1704243A4 (de) | 2007-06-06 |
| US8759307B2 (en) | 2014-06-24 |
| US20050171044A1 (en) | 2005-08-04 |
| US20150126722A1 (en) | 2015-05-07 |
| CA2550642C (en) | 2013-10-22 |
| WO2005065268A3 (en) | 2006-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1704243A4 (de) | Oligonukleotidverbindung und verfahren zur behandlung von nidovirusinfektionen | |
| ATE491791T1 (de) | Oligonukleotidanalog und verfahren zur behandlung von flavivirusinfektionen | |
| ATE467688T1 (de) | Antivirale antisense-verbindung und verfahren zur behandlung von arenavirus-infektion | |
| ATE546456T1 (de) | Triheterocyclische verbindungen, zusammensetzungen, und verfahren zur behandlung von krebs | |
| ATE503764T1 (de) | Inhibitoren des hepatitis-c-virus | |
| EP1507791A4 (de) | Antisense-antivirusmittel und verfahren zur behandlung einer ssrna-virusinfektion | |
| DE602008004317D1 (de) | Verbindungen zur behandlung von hepatitis c | |
| ATE522532T1 (de) | Verbindungen zur behandlung von hepatitis c | |
| DE602005025751D1 (de) | Verfahren und zusammensetzungen zur verringerung von hcv virusgenommengen in einer zielzelle | |
| EA200900298A1 (ru) | Ингибиторы вируса гепатита с | |
| ATE327246T1 (de) | Hepatitis c tripeptid inhibitoren | |
| PE20050204A1 (es) | Compuestos inhibidores de la hepatitis c | |
| CY1111212T1 (el) | Θειικες ενωσεις ως αναστολεις της πρωτεασης σερινης ns3 του ιου της ηπατιτιδας γ | |
| ATE540116T1 (de) | Antivirale antisense-verbindungen und verfahren zur behandlung von filovirus-infektionen | |
| ATE481106T1 (de) | Heterocyclische sulfonamid-hepatitis-c-virus- hemmer | |
| ATE413411T1 (de) | Substituierte cycloalkyl p1' hepatitis c virus inhibitoren | |
| EA201001273A1 (ru) | Ингибиторы вируса гепатита с | |
| ATE383160T1 (de) | Phosphinsäurederivate, inhibitoren von beta- sekretase zur behandlung von alzheimer-krankheit | |
| DE602004031435D1 (de) | Cycloalkyl-heterozyklen zur behandlung des hepatitis-c-virus | |
| ATE444749T1 (de) | Benzothiazolium verbindungen zur verwendung in methoden zur hemmung der no produktion und von tnf alpha und zur behandlung von coronavirus infektionen | |
| CY1110797T1 (el) | Συνθεσεις για προληψη ελκων σε αλογα | |
| IS5956A (is) | Notkun bisfosónsýra til varnar og meðhöndlunar sýkingaferla | |
| ATE491952T1 (de) | Screening auf inhibitoren des eindringens von hepatitis-c-virus | |
| DK0975588T3 (da) | Antipicornavirale forbindelser, sammensætninger indeholdende dem og fremgangsmåder til deres anvendelse | |
| RU2008125106A (ru) | Композиция для обработки волос, содержащая акриловый адгезив, чувствительный к давлению |